Author: Full-Life Technologies

Full-Life Technologies Reports First-in-Human Imaging Data for c-MET-Targeting Theranostic Ligand FL-261 Showing Robust Tumor Uptake, High Lesion Contrast and No Tracer-Related Serious Adverse Events in Patients with NSCLC

October 19, 2026
Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial

September 9, 2026

Full-Life Technologies Reports First-in-Human Imaging Data for c-MET-Targeting Theranostic Ligand FL-261 Showing Robust Tumor Uptake, High Lesion Contrast and No Tracer-Related Serious Adverse Events in Patients with NSCLC